Adding radium-223 to treatment with enzalutamide and a bone-protecting agent improved rPFS and OS in patients with mCRPC and ...

Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.

The addition of radium-223 to enzalutamide led to significant rPFS and OS benefits compared to enzalutamide alone in metastatic castration-resistant prostate cancer. Adding radium-223 (Xofigo) to ...

Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived ...

The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate cancer improved quality of life and tolerability compared to the reverse ...

Nilsson and colleagues conducted a small, randomized, placebo-controlled, phase II trial of the alpha-emitter radium-223 (223 Ra) for the treatment of these patients. A phase I trial in patients ...

Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases. Combining radium-223 (Xofigo) with ...

Methods This agent is radium-223 dichloride, also known as Xofigo®. A full treatment of Xofigo® includes six intravenous injections (dose based on patient weight) given at four week intervals. Results ...

Objectives Radium-223 dichloride (Xofigo) is a new alpha-emitting radiopharmaceutical approved by FDA for treatment of castration resistant prostate cancer bone metastases. An experiment was carried ...

Radium-223 was safe and associated with better survival and symptomatic skeletal event rates Concomitant therapies were fine, including external beam radiation or bisphosphonates, and any “old” ...

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a discussant presentation by Dr. Deborah Mukherji discussing two abstracts including “RAPSON: Open-label, ...

自进入临床以来，Ra-223积累了丰富的循证证据。整体而言，其临床应用是逐渐由后线治疗向早期治疗迈进，并在联合治疗策略中展现出令人振奋的疗效潜力。本次ESMO公布的RAPSON研究结果为早期启动Ra-223提供了新的证据，更重要的是为患者提供了更佳的 ...